Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation
Journal of Thoracic Oncology, 06/30/09
Davies AM et al. - The authors report the first clinical trial to test intermittent erlotinib plus pemetrexed. Pemetrexed 500 mg/m2 and weekly erlotinib 1400 mg (arm A) or pemetrexed 500 mg/m2 and erlotinib 250 mg on days 2 to 16 (arm B) are feasible and well tolerated. Arm B efficacy is being examined in a randomized phase II trial for second-line NSCLC.
Related Articles
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
Lung Cancer, 10/07/09
Relevance Score: 87%
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Cancer Science, 11/16/09
Relevance Score: 85%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 85%
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Journal of Clinical Oncology, 11/12/09
Relevance Score: 83%
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhaled Corticosteroids Should Be Initiated Before Discharge from the Emergency Department in Patients with Persistent Asthma
Journal of Asthma, 12/15/09
Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma
European Respiratory Journal , 12/15/09
Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
International Journal of Clinical Oncology, 12/15/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
A Small Step Towards Personalized Medicine for Non-small Cell Lung Cancer
Discovery Medicine, 12/15/09
Usefulness of fluoro-2-deoxyglucose positron emission tomography for investigating unexplained rising carcinoembryonic antigen levels that occur during the postoperative surveillance of lung cancer patients
International Journal of Clinical Oncology, 12/15/09
Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
International Journal of Clinical Oncology, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


